Here, is the CLINICAL TRIAL OF THE DAY The interesting clinical study with impact on future clinical practice // Our editor's opinion only //
France
Joined April 2022
- Tweets936
- Following70
- Followers274
- Likes396
Progression-free survival differed significantly among arbitrarily defined endocrine sensitivity groups in metastatic #breastcancer #SABCS23
Dr. Barrios highlights how very different hormone receptor positive metastatic breast cancer can be—and compares to the Aurora trial’s validation of those definitions #SABCS23 @OncoAlert
In hemodynamically unstable brain-dead potential heart donors, intravenous levothyroxine infusion did not result in significantly more hearts being transplanted than saline infusion
bit.ly/4ajRofW
#DataViz #visualabstract
DeLLphi-301 trial: #tarlatamab showed antitumor activity with durable objective responses and promising survival outcomes in patients with previously treated small-cell #lungcancer
bit.ly/3RDR98e
#DataViz #visualabstract
#FLAURA2 trial: first-line treatment with #osimertinib-#chemotherapy led to a significantly longer PFS than osimertinib monotherapy among patients with #EGFR-mutated advanced #NSCLC
bit.ly/3GoNuop
#visualabstract #DataViz #cancertwi @dplanchard
#GRADUATE clinical trials: #gantenerumab led to a lower amyloid plaque burden than placebo in #AlzheimersDisease but was not associated with slower clinical decline
bit.ly/3uxobxN
#visualabstract #DataViz #Alzheimers @Roche
#ARTESIA trial: in patients with subclinical #atrialfibrillation, #apixaban resulted in a lower risk of #stroke or #systemicembolism than aspirin but a higher risk of major bleeding
bit.ly/40MMm7l
#visualabstract #dataviz #AF
#CheckMate 901 trial: #nivolumab plus gemcitabine–cisplatin resulted in significantly better outcomes in patients with previously untreated advanced #urothelialcarcinoma than gemcitabine–cisplatin alone
bit.ly/3uao9eV
#DataViz #visualabstract
Spasertan failed to improve focal segmental glomerulosclerosis outcomes compared to irbesartan
bit.ly/478b5Ft
#VisualAbstract #nephrology #kidney #KidneyTwitter
ENVISION trial: in patients with IgA #nephropathy, 12 months of treatment with #sibeprenlimab resulted in a significantly greater decrease in proteinuria than placebo
bit.ly/46b8Xvo
#dataviz #visualabstract @Visterra_Inc #ASN2023 #ASN #kidneyweek @IgAN_JBarratt
Final overall survival analysis from KEYNOTE-826 shows sustainable benefit with first-line #pembrolizumab in persistent, recurrent,
or metastatic cervical #cancer
bit.ly/3Sq4QbO
#VisualAbstract #oncology
Treatment with #thalidomide resulted in a reduction in bleeding in patients with recurrent bleeding due to small-intestinal #angiodysplasia
bit.ly/3FJw85b
#visualabstract #dataviz
After release of EMBARK trial results the question if failure to fulfill primary endpoint will jeopardize Elevidys™ full approval for Duchenne muscular dystrophy stands
bit.ly/46TY0PY
AiDAPT ISRCTN Registry: hybrid closed-loop therapy significantly improved maternal #glycemiccontrol during #pregnancy complicated by type 1 #diabetes
bit.ly/3QRFQZX
#dataviz #visualabstract
EV-302/KEYNOTE-A39: #enfortumab vedotin + #pembrolizumab improved overall survival by 53% compared to platinum-based chemotherapy in urothelial #cancer
Enfortumab vedotin & Pembrolizumab improving PFS & OS by 55% & 53% respectively compared to platinum based chemo in 1st line UC (+avelumab in 30%). Chemo has not been beaten before (despite multiple efforts). RR and CR of 68% & 29% is hard to beat. DOR not reached (1/3)#ESMO2023
AEGEAN trial: in resectable #NSCLC, perioperative #durvalumab was associated with significantly greater event-free survival and pathological complete response than neoadjuvant chemotherapy alone
bit.ly/46Tyqus
#visualabstract #dataviz #cancertwi #lungcancer @FouadMD
Radulotatug deruxtecan demonstrated impressive response rates in heavily pretreated platinum-resistant #OvarianCancer patients
#VisualAbstract #oncology #cancer #ESMO2023
Second interim analysis from LITESPARK-005 Trial demonstrated significant improvement in primary endpoint of progression free survival accompanied by better QoL compared to everolimus treatment in pretreated renal #cancer
#VisualAbstract #oncology #ESMO2023
New data from NATALEE trial indicate sustained invasive disease-free survival for adjuvant ribociclib in all major subgroups of early #breastcancer patients
bit.ly/45GmNWr
#VisualAbstract #oncology #ESMO23
Two short courses of teplizumab allowed to diminish progression of newly diagnosed type 1 #diabetes , yet failed to improve glycemic control
bit.ly/46ZXfEZ
#VisualAbstract #endocrinology
ATLANTIS trial: titrated low-dose #amitriptyline was superior to placebo as a second-line treatment for #IBS across multiple outcomes, and was safe and well tolerated
bit.ly/3tByP66
#visualabstract #dataviz #gastrotwi #Gastroenterology @amanda_horler
